Moderna withdraws COVID-flu vaccine application, plans resubmission later in the year

From Yahoo Finance: 2025-05-21 20:15:00

Moderna, Inc. (NASDAQ:MRNA) withdraws application for COVID-flu combination vaccine after voluntarily pulling pending Biologics License Application seeking approval for adults aged 50 and older. Company plans to resubmit later in the year after efficacy data from ongoing trial of mRNA-1010 influenza shot.

FDA tightens COVID-19 vaccine requirements, planning new trials for annual booster shots for healthy Americans under 65. Moderna, Inc. (NASDAQ:MRNA) faces increased regulatory scrutiny and stock struggles with 8% plunge on Wednesday, year-to-date slump at 38%.

Moderna, Inc. (NASDAQ:MRNA) gained recognition for developing effective coronavirus vaccine but faces challenges with stock performance and regulatory environment. Company’s struggles reflected in 8% stock plunge on Wednesday. Consider AI stocks for higher potential returns and limited downside risk compared to MRNA.



Read more at Yahoo Finance: Moderna, Inc. (MRNA) Withdraws Application for COVID-flu Combination Vaccine